Table 1. The baseline data of enrolled participants in both groups.
| Variables | AUR (n=85) | AUR-free (n=171) | P value |
|---|---|---|---|
| Age, years | 72.00 (66.00–80.00) | 70.00 (65.00–76.00) | 0.134‡ |
| BMI, kg/m2 | 22.41 (21.30–23.39) | 22.79 (21.67–23.83) | 0.141‡ |
| DM, n (%) | 0.886§ | ||
| Yes | 13 (15.29) | 25 (14.62) | |
| No | 72 (84.71) | 146 (85.38) | |
| Neuropathy, n (%) | 1.000§ | ||
| Yes | 3 (3.53) | 5 (2.92) | |
| No | 82 (96.47) | 166(97.08) | |
| CVD, n (%) | 0.355§ | ||
| Yes | 7 (8.24) | 9 (5.26) | |
| No | 78 (91.76) | 162 (94.74) | |
| Hypertension, n (%) | 0.195§ | ||
| Yes | 40 (47.06) | 66 (38.60) | |
| No | 45 (52.94) | 105 (61.40) | |
| Alcohol drinking, n (%) | 0.192§ | ||
| Yes | 15 (17.65) | 20 (11.70) | |
| No | 70 (82.35) | 151 (88.30) | |
| Cigarette smoking, n (%) | 0.431§ | ||
| Yes | 19 (22.35) | 46 (26.90) | |
| No | 66 (77.65) | 125 (73.10) | |
| t-PSA, ng/mL | 6.79 (3.86–13.15) | 3.98 (2.18–8.01) | <0.001‡ |
| f-PSA, ng/mL | 1.30 (0.72–2.50) | 0.81 (0.45–1.44) | <0.001‡ |
| f/t-PSA | 0.19 (0.14–0.26) | 0.22 (0.17–0.27) | 0.034‡ |
| PSAD, ng/mL/mL | 0.09 (0.06–0.14) | 0.06 (0.03–0.10) | <0.001‡ |
| TPV, mL | 74.13 (46.79–99.01) | 61.77 (43.86–86.42) | 0.047‡ |
| TZV, mL | 47.57 (25.08–64.05) | 31.97 (17.31–56.64) | 0.018‡ |
| TZI | 0.57±0.15 | 0.52±0.15 | 0.009† |
| IPP, mm | 12.50 (10.25–15.75) | 14.00 (8.00–17.00) | 0.614‡ |
| Qmax, mL/s | 3.05 (1.60–5.63) | 5.50 (3.30–7.35) | <0.001‡ |
| PdetQmax, cmH2O | 80.40 (63.50–108.00) | 68.90 (46.90–89.20) | 0.019‡ |
| I-PSS | 25.00 (22.50–27.00) | 22.00 (16.00–25.00) | <0.001‡ |
| sIL-6, pg/mL | 5.23 (3.25–8.74) | 2.85 (2.00–3.95) | <0.001‡ |
| TT, nmol/L | 13.68 (11.11–16.79) | 13.32 (11.13–17.13) | 0.993‡ |
| TP, g/L | 64.63±5.04 | 65.42±5.48 | 0.264† |
| Alb, g/L | 38.26±4.16 | 39.41±3.91 | 0.032† |
| Cr, μmol/L | 74.00 (65.00–88.50) | 73.00 (67.00–83.00) | 0.974‡ |
| UA, μmol/L | 335.85±80.42 | 343.02±77.13 | 0.490† |
| TG, mmol/L | 0.98 (0.70–1.46) | 1.24 (0.83–1.87) | 0.004‡ |
| TC, mmol/L | 4.21±0.87 | 4.22±0.86 | 0.993† |
| LDL-c, mmol/L | 2.38±0.68 | 2.38±0.69 | 0.953† |
| HDL-c, mmol/L | 1.33 (1.15–1.64) | 1.23 (1.07–1.46) | 0.032‡ |
| Glu, mmol/L | 5.02 (4.66–5.79) | 5.21 (4.70–5.87) | 0.194‡ |
| CRP, mg/L | 4.00 (2.00–7.00) | 5.00 (2.00–7.00) | 0.410‡ |
| Blood WBC, ×109/L | 6.20 (4.95–7.20) | 6.00 (5.00–7.30) | 0.830‡ |
| Urine WBC, /HP | 1.00 (0.00–5.00) | 1.00 (0.00–4.00) | 0.922‡ |
Data are presented as the mean ± standard deviation (SD), the median (interquartile range), or the frequency (%). †, Student’s t-test; ‡, Mann-Whitney U test; §, Chi-squared test or Fisher’s exact test. AUR, acute urinary retention; BMI, body mass index; DM, diabetes mellitus; CVD, cardiovascular disease; t-PSA, total prostate-specific antigen; f-PSA, free prostate-specific antigen; f/t-PSA, free to total prostate-specific antigen ratio; PSAD, prostate-specific antigen density; TPV, total prostate volume; TZV, transitional zone volume; TZI, transitional zone index; IPP, intravesical prostatic protrusion; Qmax, maximum flow rate, PdetQmax, detrusor pressure at maximum flow rate; I-PSS, International Prostate Symptom Score; sIL-6, serum interleukin 6; TT, total testosterone; TP, total protein; Alb, albumin; Cr, creatinine; UA, uric acid; TG, triglycerides; TC, total cholesterol; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; Glu, plasma glucose; CRP, C-reactive protein; WBC, white blood cell.